Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

Entrectinib is a pan-tyrosine-kinase inhibitor that targets oncogenic rearrangements in NTRK, ROS1 and ALK. The combined results of two clinical trials demonstrated the efficacy of entrectinib in ROS1-rearranged NSCLC. Because the development of drug resistance is inevitable, it would be helpful to...

全面介紹

Na minha lista:
書目詳細資料
發表在:Invest New Drugs
Main Authors: Ku, Bo Mi, Bae, Yeon Hee, Lee, Kyoung Young, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
格式: Artigo
語言:Inglês
出版: Springer US 2019
主題:
Preclinical Studies
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066105/
https://ncbi.nlm.nih.gov/pubmed/31124056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00795-3
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍